437 related articles for article (PubMed ID: 18212512)
1. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease.
Palleschi S; De Angelis S; Rossi B; Diana L; Papa V; Severini G; Splendiani G
Nephron Clin Pract; 2008; 108(2):c106-12. PubMed ID: 18212512
[TBL] [Abstract][Full Text] [Related]
2. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
3. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
Dierkes J; Domröse U; Ambrosch A; Bosselmann HP; Neumann KH; Luley C
Clin Nephrol; 1999 Feb; 51(2):108-15. PubMed ID: 10069646
[TBL] [Abstract][Full Text] [Related]
4. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.
Apeland T; Frøyland ES; Kristensen O; Strandjord RE; Mansoor MA
Epilepsy Res; 2008 Nov; 82(1):1-6. PubMed ID: 18644700
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
7. The aminothiol redox status in haemodialysis patients does not improve with folate therapy.
Apeland T; Kristensen O; Mansoor MA
Scand J Clin Lab Invest; 2009; 69(2):265-71. PubMed ID: 18972259
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
[TBL] [Abstract][Full Text] [Related]
9. Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients.
Brunetti M; Terracina L; Timio M; Saronio P; Capodicasa E
J Nephrol; 2001; 14(1):27-31. PubMed ID: 11281340
[TBL] [Abstract][Full Text] [Related]
10. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols.
Di Giuseppe D; Frosali S; Priora R; Di Simplicio FC; Buonocore G; Cellesi C; Capecchi PL; Pasini FL; Lazzerini PE; Jakubowski H; Di Simplicio P
J Lab Clin Med; 2004 Nov; 144(5):235-45. PubMed ID: 15570241
[TBL] [Abstract][Full Text] [Related]
11. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia.
Di Giuseppe D; Di Simplicio P; Capecchi PL; Lazzerini PE; Pasini FL
J Lab Clin Med; 2003 Jul; 142(1):21-8. PubMed ID: 12878982
[TBL] [Abstract][Full Text] [Related]
12. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
Righetti M; Serbelloni P; Milani S; Ferrario G
Blood Purif; 2006; 24(4):379-86. PubMed ID: 16755160
[TBL] [Abstract][Full Text] [Related]
14. Relationships between homocysteine and related amino acids in chronic hemodialysis patients.
McDonald SP; Whiting MJ; Tallis GA; Barbara JA
Clin Nephrol; 2001 Jun; 55(6):465-70. PubMed ID: 11434358
[TBL] [Abstract][Full Text] [Related]
15. Plasma homocysteine concentration changes after renal transplantation in children.
Merouani A; Delvin EE; Genest J; Rozen R; Lambert M
Pediatr Nephrol; 2002 Jul; 17(7):520-3. PubMed ID: 12172766
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia in children on renal replacement therapy.
Feinstein S; Sela BA; Drukker A; Becker-Cohen R; Raveh D; Gavendo S; Frishberg Y
Pediatr Nephrol; 2002 Jul; 17(7):515-9. PubMed ID: 12172765
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.
Beavers KM; Beavers DP; Bowden RG; Wilson RL; Gentile M
Nephrology (Carlton); 2008 Jun; 13(4):284-8. PubMed ID: 18331436
[TBL] [Abstract][Full Text] [Related]
18. Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation.
Stopper H; Treutlein AT; Bahner U; Schupp N; Schmid U; Brink A; Perna A; Heidland A
Nephrol Dial Transplant; 2008 Oct; 23(10):3272-9. PubMed ID: 18469307
[TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
[TBL] [Abstract][Full Text] [Related]
20. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.
Vrentzos GE; Papadakis JA; Vardakis KE; Maliaraki N; Stilianou K; Arvanitis A; Sratigis S; Alivanis P; Margioris AN; Ganotakis ES
J Nephrol; 2003; 16(4):535-9. PubMed ID: 14696755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
